Interleukin-17 promotes angiogenesis and tumor growth

被引:680
作者
Numasaki, M
Fukushi, J
Ono, M
Narula, SK
Zavodny, PJ
Kudo, T
Robbins, PD
Tahara, H
Lotze, MT
机构
[1] Tohoku Univ, Sch Med, Dept Geriatr & Resp Med, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Sch Med, Dept Mol Genet, Pittsburgh, PA 15260 USA
[4] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Sch Med, Dept Biochem, Pittsburgh, PA 15260 USA
[5] Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Fukuoka 812, Japan
[6] Schering Plough Corp, Res Inst, Dept Immunol, Kenilworth, NJ 07033 USA
[7] Tohoku Univ, Inst Dev Aging & Canc, Cell Resource Ctr Biomed Res, Sendai, Miyagi 980, Japan
关键词
D O I
10.1182/blood-2002-05-1461
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interleukin-117 (IL-17) is a CD4 T-cell-derived proinflammatory cytokine. We investigated the effects of locally produced IL-17 by tumors as a means to evaluate its biologic function. Although recombinant IL-17 protein or retroviral transduction of IL-17 gene into tumors did not affect in vitro proliferation, IL-17 transfectants grew more rapidly in vivo when compared with controls. Immunostaining for Factor VIII revealed that tumors transduced with IL-17 had significantly higher vascular density when compared with controls. IL-17 indeed elicited neovascularization in rat cornea. In addition, angiogenic activity present in the conditioned media of CD4 T cells was markedly suppressed by neutralizing monoclonal antibody to IL-17. IL-17 had no direct effect on the growth of vascular endothelial cells, whereas IL-17 significantly stimulated migration. IL-17 also markedly promoted the cord formation of vascular endothelial cells. In addition, IL-17 up-regulated elaboration of a variety of proangiogenic factors by fibroblasts as well as tumor cells. These findings reveal a novel role for IL-17 as a CD4 T-cell-derived mediator of angiogenesis that stimulates vascular endothelial cell migration and cord formation and regulates production of a variety of proangiogenic factors. Furthermore, they suggest that inhibition of biologic action of IL-17 May have therapeutic benefits when applied to angiogenesis-related disorders.
引用
收藏
页码:2620 / 2627
页数:8
相关论文
共 42 条
[1]  
Aarvak T, 1999, J IMMUNOL, V162, P1246
[2]   The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity [J].
Addison, CL ;
Daniel, TO ;
Burdick, MD ;
Liu, H ;
Ehlert, JE ;
Xue, YY ;
Buechi, L ;
Walz, A ;
Richmond, A ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (09) :5269-5277
[3]  
Awane M, 1999, J IMMUNOL, V162, P5337
[4]   Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism [J].
Benchetrit, F ;
Ciree, A ;
Vives, V ;
Warnier, G ;
Gey, A ;
Sautès-Fridman, C ;
Fossiez, F ;
Haicheur, N ;
Fridman, WH ;
Tartour, E .
BLOOD, 2002, 99 (06) :2114-2121
[5]   INDIRECT ANGIOGENIC CYTOKINES UP-REGULATE VEGF AND BFGF GENE-EXPRESSION IN VASCULAR SMOOTH-MUSCLE CELLS, WHEREAS HYPOXIA UP-REGULATES VEGF EXPRESSION ONLY [J].
BROGI, E ;
WU, TG ;
NAMIKI, A ;
ISNER, JM .
CIRCULATION, 1994, 90 (02) :649-652
[6]   CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor [J].
Cho, CS ;
Cho, ML ;
Min, SY ;
Kim, WU ;
Min, DJ ;
Lee, SS ;
Park, SH ;
Choe, J ;
Kim, HY .
JOURNAL OF IMMUNOLOGY, 2000, 164 (10) :5055-5061
[7]   VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].
DRANOFF, G ;
JAFFEE, E ;
LAZENBY, A ;
GOLUMBEK, P ;
LEVITSKY, H ;
BROSE, K ;
JACKSON, V ;
HAMADA, H ;
PARDOLL, D ;
MULLIGAN, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543
[8]  
FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
[9]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[10]  
FORM DM, 1983, P SOC EXP BIOL MED, V172, P214